摘要
目的探讨CD56,CD95,Ki-67,p53,bcl-2,HMB45和S-100在恶性黑色素瘤中的表达,旨在提高黏膜无色素性恶性黑色素瘤的病理诊断率,减少误诊和漏诊,并为临床估计预后、选择治疗方案提供客观指标。方法应用组织芯片和免疫组织化学标记技术,对48例黏膜无色素性恶性黑色素瘤进行标记和分析。结果HMB45与S-100的阳性率分别是100%和85%(41/48)。CD56的阳性率为92%(44/48),在转移灶与原发病例中,两者差异无统计学意义(P>0.05)。CD95的阳性率为85%(41/48),其中11例有淋巴结转移病例,阳性率达100%,Ki-67与p53阳性率是79%(38/48)和58%(28/48)。Ki-67的阳性分布与CD95基本一致。bcl-2的阳性率为40%(19/48)。p53和bcl-2在恶性黑色素瘤中的表达阳性率与CD95比较,差异有统计学意义(P<0.05)。结论CD56在黏膜无色素性恶性黑色素瘤中具有重要的辅助诊断价值;CD95(Fas)与Ki-67的表达对判断恶性黑色素瘤浸润范围及淋巴结转移状况和指导临床治疗有一定的意义。
Objective To investigate CD56, CD95, Ki-67, p53, bel-2, HMB45 and S-100 expression of malignant melanoma and enhance the diagnosis level of it. And it is a guide for the therapy. Methods The technique of tissue chips and immunohistochemical labelling was used for analysing 48 cases of amelanotic malignant melamoma. Results The positive rates of HMB45 and S-100 are 100% （48/48） and 85% （41/48）. The positive rate of CD56 was 92% （44/48） ;no statistical difference was found in origninal cases and metastatic eases. The positive rate of CD95 was 85 % （41/48）, but 11 cases of lymphaden metastasis had positive rate 100% （11/11 ）. The positive rates of Ki-67 and p53 were 79% （38/48） and 58% （28/48）. The positive distribution of Ki-67 was was almost same as that of CD95. The positive rate of bel-2 was 40% （19/48）. There was a significant difference of positivity between p53 and bel-2 （P〈 0.05）.Conclusion CD56 hase important role in the diagnosis of mucous amelanotic malignant melanoma. The expression of CD95 （Fas） and Ki-67 plays some role in assessing the condition of invasion region and lymphaden metastasis of malignant melanoma.
出处
《山西医药杂志》
CAS
2005年第8期637-639,共3页
Shanxi Medical Journal
